Safety Study of a Monoclonal Antibody to Respiratory Syncytial Virus (RSV) in Children Hospitalized With RSV Infection

NCT00192504 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

31

Enrollment

INDUSTRY

Sponsor class

Conditions

Respiratory Syncytial Virus Prophylaxis

Interventions

BIOLOGICAL: Motavizumab
BIOLOGICAL: Motavizumab
BIOLOGICAL: Motavizumab
OTHER: Placebo

Sponsor

MedImmune LLC